Zai Lab Ltd stock (KYG9887Y1016): FDA fast track for cancer ADC

Zai Lab Ltd announced that the U.S. FDA has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), its potential first-in-class DLL3-targeting antibody-drug conjugate (ADC), for treating extrapulmonary neuroendocrine carcinomas (epNECs) after progression on standard first-line therapy, according to Marketscreener as of May 2026. The stock rose 7.2% on Monday following the news, trading at $19.59 on Nasdaq after a 5.32% gain, per StockInvest.us as of 05/11/2026. This marks the second fast track for zoci, after ES-SCLC approval in May 2025.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Zai Lab Ltd: core business model

Zai Lab Ltd is a biotechnology company focused on discovering, developing, and commercializing innovative therapies, primarily in oncology, autoimmune disorders, and infectious diseases, with a strong emphasis on the Greater China market. The company partners with global biotech firms to in-license promising assets for commercialization in China, according to its investor relations site as of 05/2026. Zai Lab operates from headquarters in China while listed on Nasdaq as ZLAB.

This model allows Zai Lab to leverage partnerships for pipeline expansion without full R&D costs, targeting high-unmet-need areas like small cell lung cancer and neuroendocrine tumors. The firm's strategy emphasizes rapid regulatory approvals in China via innovative pathways.

Main revenue and product drivers for Zai Lab Ltd

Zai Lab's revenue is driven by commercialized products like Zejula (from GSK) for ovarian cancer and Vyvgart (from argenx) for myasthenia gravis, both approved in China. Oncology remains the core, with zoci positioned as a potential first global launch candidate, per Marketscreener as of May 2026. The company reported a market cap of $2.08 billion USD as of May 10, 2026, via Nasdaq data on CompaniesMarketCap as of 05/2026.

Pipeline advancements, such as the recent FDA fast track, bolster growth prospects. Zai Lab also granted new share options and RSUs under its 2024 equity plan, as announced recently per TipRanks as of May 2026.

Industry trends and competitive position

The ADC market is booming, with DLL3-targeting therapies addressing aggressive cancers like epNECs where options are limited post-first-line. Zai Lab's zoci differentiates via its bispecific design, potentially improving efficacy over competitors. Fast track status accelerates US and global development, relevant for US investors tracking biotech innovation.

Why Zai Lab Ltd matters for US investors

Listed on Nasdaq, Zai Lab offers US investors exposure to China's fast-growing biotech sector, with zoci's FDA fast track signaling potential US market entry. The stock's volatility ties to clinical milestones, providing opportunities amid US-China healthcare convergence.

Conclusion

Zai Lab Ltd's FDA fast track for zoci highlights pipeline momentum in oncology ADCs, driving recent share gains amid a $2.08 billion market cap. Equity grants signal employee incentives, while Nasdaq listing ensures US investor access. Developments warrant monitoring for biotech enthusiasts focused on innovative therapies.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.